Copper Lowering Therapy With Tetrathiomolybdate as an Antiangiogenic Strategy in Cancer

E-ISSN： 1873-5576|5|3|195-202

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.5, Iss.3, 2005-05, pp. : 195-202

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer

By Gartner Elaina Griffith Kent Pan Quintin Brewer George Henja Gwen Merajver Sofia Zalupski Mark

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 159-165

Springer Publishing Company

Access to resources Recommend Favorite

The use of copper-lowering therapy with tetrathiomolybdate in medicine

By Brewer George J

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 1, 2009-01 ,pp. : 89-97

Informa Healthcare

Access to resources Recommend Favorite

Copper chelation in cancer therapy using tetrathiomolybdate: an evolving paradigm

By Khan Gazala Merajver Sofia

Expert Opinion on Investigational Drugs, Vol. 18, Iss. 4, 2009-04 ,pp. : 541-548

Informa Healthcare

Access to resources Recommend Favorite

Antiangiogenic therapy through copper chelation

By Sproull Mary Brechbiel Martin Camphausen Kevin

Expert Opinion on Therapeutic Targets, Vol. 7, Iss. 3, 2003-06 ,pp. : 405-409

Informa Healthcare

Access to resources Recommend Favorite

Antibody-based antiangiogenic cancer therapy

By Sanz Laura Álvarez-Vallina Luis

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 6, 2005-12 ,pp. : 1235-1245

Informa Healthcare

Access to resources Recommend Favorite